Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “underweight” rating reissued by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, Marketbeat Ratings reports.
A number of other research analysts have also issued reports on PLRX. Weiss Ratings restated a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Wednesday. Piper Sandler cut their target price on shares of Pliant Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research report on Friday, August 8th. Finally, Citigroup restated a “neutral” rating on shares of Pliant Therapeutics in a research report on Sunday, August 10th. One analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pliant Therapeutics currently has an average rating of “Reduce” and an average target price of $8.19.
Check Out Our Latest Stock Analysis on Pliant Therapeutics
Pliant Therapeutics Stock Down 4.5%
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.09). Sell-side analysts predict that Pliant Therapeutics will post -3.64 EPS for the current year.
Institutional Investors Weigh In On Pliant Therapeutics
A number of large investors have recently bought and sold shares of PLRX. Jump Financial LLC acquired a new stake in Pliant Therapeutics in the second quarter worth $30,000. Engineers Gate Manager LP boosted its holdings in Pliant Therapeutics by 139.4% during the second quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock worth $36,000 after purchasing an additional 18,300 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in Pliant Therapeutics during the second quarter worth about $36,000. Catalyst Funds Management Pty Ltd bought a new stake in Pliant Therapeutics in the second quarter worth about $39,000. Finally, Vanguard Personalized Indexing Management LLC raised its position in Pliant Therapeutics by 119.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 35,540 shares of the company’s stock worth $41,000 after acquiring an additional 19,320 shares during the period. 97.30% of the stock is currently owned by institutional investors and hedge funds.
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Featured Articles
- Five stocks we like better than Pliant Therapeutics
- ESG Stocks, What Investors Should Know
- Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
- Using the MarketBeat Stock Split Calculator
- AST SpaceMobile’s Big Win: Shares Soar on New Deal With Verizon
- The Significance of Brokerage Rankings in Stock Selection
- Catch the Next Bitcoin Rally With These 3 ETFs
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.